Terms: = Breast cancer AND P2RY8, RP11-261P4_4, 286530, ENSG00000182162, MGC50878, P2Y8, Q86VZ1 AND Treatment
30804 results:
1. Development and validation of a nomogram for predicting the occurrence of renal dysfunction after treatment of immune checkpoint inhibitor: a retrospective case-control study.
Su J; Chen P; Yang Y; Gao Z; Bi Z; Feng M
BMJ Open; 2024 May; 14(5):e082484. PubMed ID: 38760047
[TBL] [Abstract] [Full Text] [Related]
2. Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease.
Salim N; Tumanova K; Popodko A; Libson E
JCO Glob Oncol; 2024 May; 10():e2300275. PubMed ID: 38754052
[TBL] [Abstract] [Full Text] [Related]
3. Dietary supplement intake in women with breast cancer before and after diagnosis: results from the SUCCESS C trial.
Hauner D; Mang A; Donik L; Schederecker F; Meyer D; Rack B; Janni W; Hauner H
BMC Cancer; 2024 May; 24(1):591. PubMed ID: 38750410
[TBL] [Abstract] [Full Text] [Related]
4. Practice of breast self-examination and associated factors among women of reproductive age in the North Shoa Zone, Oromia, Ethiopia, 2022: a convergent mixed-methods study.
Hussein D; Oyato BT; Gashaw K; Geleta TA; Tufa DG; Geleta LA
BMJ Open; 2024 May; 14(5):e073951. PubMed ID: 38749697
[TBL] [Abstract] [Full Text] [Related]
5. Enhancing pathological complete response prediction in breast cancer: the role of dynamic characterization of DCE-MRI and its association with tumor heterogeneity.
Zhang X; Teng X; Zhang J; Lai Q; Cai J
Breast Cancer Res; 2024 May; 26(1):77. PubMed ID: 38745321
[TBL] [Abstract] [Full Text] [Related]
6. Magnetically modified-mitoxantrone mesoporous organosilica drugs: an emergent multimodal nanochemotherapy for breast cancer.
Romaní-Cubells E; Martínez-Erro S; Morales V; Chocarro-Calvo A; García-Martínez JM; Sanz R; García-Jiménez C; García-Muñoz RA
J Nanobiotechnology; 2024 May; 22(1):249. PubMed ID: 38745193
[TBL] [Abstract] [Full Text] [Related]
7. An Immersive Virtual Reality Intervention for Preoperative Anxiety and Distress Among Adults Undergoing Oncological Surgery: Protocol for a 3-Phase Development and Feasibility Trial.
El-Gabalawy R; Sommer JL; Hebbard P; Reynolds K; Logan GS; Smith MSD; Mutter TC; Mutch WA; Mota N; Proulx C; Gagnon Shaigetz V; Maples-Keller JL; Arora RC; Perrin D; Benedictson J; Jacobsohn E
JMIR Res Protoc; 2024 May; 13():e55692. PubMed ID: 38743939
[TBL] [Abstract] [Full Text] [Related]
8. Longitudinal assessment of real-world patient adherence: a 12-month electronic patient-reported outcomes follow-up of women with early breast cancer undergoing treatment.
Gebert P; Hage AM; Blohmer JU; Roehle R; Karsten MM
Support Care Cancer; 2024 May; 32(6):344. PubMed ID: 38740611
[TBL] [Abstract] [Full Text] [Related]
9. Symptomatic adverse events of chemotherapy in breast cancer patients:Using CTCAE, PRO-CTCAE, and EORTC QLQ-C30.
Arahori H; Kondo K; Imai Y; Bando T; Inoue H; Sasa S; Takizawa H
J Med Invest; 2024; 71(1.2):82-91. PubMed ID: 38735729
[TBL] [Abstract] [Full Text] [Related]
10. Advanced-stage breast cancer diagnosis and its determinants in Ethiopia: a systematic review and meta-analysis.
Zewdie A; Kassie TD; Anagaw TF; Mazengia EM; Gelaw SS; Fenta ET; Eshetu HB; Kebede N; Bogale EK
BMC Womens Health; 2024 May; 24(1):284. PubMed ID: 38734607
[TBL] [Abstract] [Full Text] [Related]
11. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
[TBL] [Abstract] [Full Text] [Related]
12. General practitioners' management of mastitis in breastfeeding women: a mixed method study in Australia.
Amir LH; Crawford SB; Cullinane M; Grzeskowiak LE
BMC Prim Care; 2024 May; 25(1):161. PubMed ID: 38730361
[TBL] [Abstract] [Full Text] [Related]
13. Psychotropic Medication Prescriptions for Home-Based Palliative Care Oncology Patients.
Mohamed F; Uvais NA; Moideen S; Cp RR; Saif M
Prim Care Companion CNS Disord; 2024 May; 26(2):. PubMed ID: 38728674
[No Abstract] [Full Text] [Related]
14. Edema of the upper extremity on the unaffected side in unilateral breast cancer patients.
Kim JH; Seong ST; Lee JH; Kim GC; Jeong HJ; Sim YJ
Medicine (Baltimore); 2024 May; 103(19):e37995. PubMed ID: 38728522
[TBL] [Abstract] [Full Text] [Related]
15. E3 ubiquitin ligase BCA2 promotes breast cancer stemness by up-regulation of SOX9 by LPS.
Zheng M; Liu W; Zhang R; Jiang D; Shi Y; Wu Y; Ge F; Chen C
Int J Biol Sci; 2024; 20(7):2686-2697. PubMed ID: 38725852
[TBL] [Abstract] [Full Text] [Related]
16. Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment.
Bardakci M; Karakas H; Bayram D; Avci N; Kitapli S; Ozen M; Aslan F; Koseoglu C; Kadioglu A; Onur ID; Sakalar T; Buyuksimsek M; Alkan A; Ergun Y; Kaya AO; Bilgin B; Yalcin B
Sci Rep; 2024 May; 14(1):10632. PubMed ID: 38724585
[TBL] [Abstract] [Full Text] [Related]
17. Declination of treatment, Racial and Ethnic Disparity, and Overall Survival in US Patients With breast cancer.
Freeman JQ; Li JL; Fisher SG; Yao KA; David SP; Huo D
JAMA Netw Open; 2024 May; 7(5):e249449. PubMed ID: 38722630
[TBL] [Abstract] [Full Text] [Related]
18. Application of Patient-Reported Outcome Measurements in Adult Tumor Clinical Trials in China: Cross-Sectional Study.
Jia Y; Li Q; Zhang X; Yan Y; Yan S; Li S; Li W; Wu X; Rong H; Liu J
J Med Internet Res; 2024 May; 26():e45719. PubMed ID: 38718388
[TBL] [Abstract] [Full Text] [Related]
19. Preexisting Diabetes and breast cancer treatment Among Low-Income Women.
Bekele BB; Lian M; Schmaltz C; Greever-Rice T; Shrestha P; Liu Y
JAMA Netw Open; 2024 May; 7(5):e249548. PubMed ID: 38717774
[TBL] [Abstract] [Full Text] [Related]
20. Prevalence of anticipatory nausea and vomiting in breast cancer patients undergoing highly emetogenic chemotherapy.
Alves RB; Rebouças CV; Yamada AMTD; Cruz FJSM
Rev Assoc Med Bras (1992); 2024; 70(4):e20230937. PubMed ID: 38716933
[TBL] [Abstract] [Full Text] [Related]
[Next]